Bristol-Myers Squibb Co news

   Watch this stock
Showing stories 1 - 10 of about 166   

Articles published

BMY 58.77 +0.01 (0.02%)
price chart
Is Gilead Sciences, Inc. (GILD) and Bristol-Myers Squibb Company (BMY) Merger ...
Gilead Sciences, Inc.'s (NASDAQ:GILD) hepatitis franchise has done a hefty contribution for the company in revenue generation, but it is now sailing at a slow pace due to reduce patients pool and introduction of new therapies in the market.
Bristol-Myers Squibb Company (NYSE:BMY): Updated Analyst Ratings  Review Fortune
Insider Trading and Recommendation Roundup: Bristol-Myers Squibb Co (NYSE:BMY)  Post Registrar
Can Bristol-Myers Squibb Co's (BMY) Eliquis Rule the Cardiovascular Segment?
Bristol-Myers Squibb Co (NYSE:BMY) is one of the largest companies that is indulged in the development and marketing of multiple categories of drugs for the management and treatment of oncology, cardiovascular disease, HIV/AIDS, diabetes, rheumatoid ...
Which way Bristol-Myers Squibb Company (NYSE:BMY) insiders are heading  Review Fortune
Bristol-Myers Squibb Co.: If This Happens, BMY Stock Could Crash  Profit Confidential
Strategy To YieldBoost Bristol-Myers Squibb Co. To 6.2% Using Options
Shareholders of Bristol-Myers Squibb Co. (Symbol: BMY) looking to boost their income beyond the stock's 2.5% annualized dividend yield can sell the January 2018 covered call at the $70 strike and collect the premium based on the $3.20 bid, which ...
Can Bristol-Myers Squibb Company (BMY) Survive Opdivo Failure?
Bristol-Myers Squibb Co. (NYSE:BMY) has faced a shock when its blockbuster molecule, Opdivo, did not meet the primary endpoints in the patients with Non-Small Cell Lung Cancer (NSCLC.
AbbVie, BMS to Develop Relapsed Extensive-Stage Small Cell Lung Cancer ...  Immuno-Oncology News
Attention Grabbing Analyst Research Reports: Bristol-Myers Squibb Co (BMY ...
Bristol-Myers Squibb Co (NYSE:BMY) remained bearish with a decrease -0.56% putting the price on the $60.63 per share in last trading session ended on 8/12/2016.
Bristol-Myers Squibb Co (BMY) Downgraded by Berenberg Following CheckMate ...  TCC
Berenberg Downgrades Bristol-Myers Squibb Co. (BMY) to Hold
Bristol-Myers Squibb Co (NYSE:BMY) Analyst Estimates
Bristol-Myers Squibb Co (NYSE:BMY) stock is currently trading at about $61.61 and lots of rating firms seem to have a target price set on the stock.
Yesterday's Analyst's Downgrade: Bristol-Myers Squibb Co (NYSE:BMY)  Review Fortune
Bristol-Myers Squibb Co: The BMY Freefall Is Overdone
Would Bristol-Myers Squibb Co (NYSE:BMY) Shares Survive Study Failure?
Morgan Stanley analyst David Risinger has downgraded his rating on Bristol-Myers Squibb from Overweight to Equal Weight due to the sudden decline in the stock.
Blockbuster cancer treatment fails in key study, Bristol-Myers shares plunge  CTV News
What Wall Street is saying about Bristol-Myers Squibb Co (NYSE:BMY)  Zergwatch
Bristol-Myers Squibb Continues to Grow in 2Q16
... and valuation. The series covers major factors and the segment-wise performance of products for a better understanding of each of these drivers.
Bristol-Myers Squibb Co (NYSE:BMY) Analyst Research Summary
Bristol-Myers Squibb Co (NYSE:BMY) stock is currently trading at about $74.81 and lots of rating firms seem to have a target price set on the stock.
Stock Earnings to Watch: Bristol-Myers Squibb Co (NYSE:BMY)  Post Registrar
Bristol-Myers Squibb Co (NYSE:BMY) & Yandex NV (NASDAQ:YNDX) Stocks in ...  Money News (press release)
Credit Suisse Downgrades Bristol-Myers Squibb Co. (BMY) to Neutral
Credit Suisse downgraded Bristol-Myers Squibb Co. (NYSE: BMY) from Outperform to Neutral with a price target of $63.00 following news Friday that its CheckMate-026 (CM-026) Study for Opdivo in 1st line non-small cell lung cancer (NSCLC) missed its ...